I agree flipper44. Too many think we are late when in fact Linda Powers, who wrote NAFTA and EU Patent Law, has logically, in my estimation, put us on rolling review. The magnitude of this application will only be understood once we get approval. I guarantee the ASCO 2023 proteomic analysis, which proved Mechanism of Action, was included in the application as regulators in my opinion must have this data. That was likely a hundred pages or more including appendices. These things simply take time. Thankfully we have laser-focused management and diehard shareholders who are steadfast in their support of this monumental effort. From my perspective no number of degenerate spoofers or manipulative swing traders will derail this upcoming Landmark approval.
Bullish